Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study
Vaccine Jan 24, 2018
Zaman K, et al. - A 4-dose vial presentation of pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was developed to support vaccination programs in developing countries. This study, conducted in Bangladesh, represented an attempt to evaluate immunologic non-inferiority and safety of the investigational PHiD-CV 4-dose vs licensed 1-dose vial presentation in infants. Findings demonstrated the immunologic non-inferiority of PHiD-CV 4-dose vial (with preservative), compared with PHiD-CV 1-dose vial (preservative-free). In addition, researchers noted that for both presentations, immune responses and reactogenicity following primary/booster vaccination were within similar ranges. Notably, PHiD-CV 4-dose vial would help improve access and coverage in resource-limited countries.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries